The Pediatric infectious disease journal
-
Pediatr. Infect. Dis. J. · Aug 2007
Pneumococcal bacteremia among infants with fever without known source before and after introduction of pneumococcal conjugate vaccine in the Basque Country of Spain.
The introduction of vaccination with the heptavalent pneumococcal conjugate vaccine (PCV7) has produced an important decrease in the incidence of Streptococcus pneumoniae occult bacteremia (OB). In Spain, PCV7 became available in the last months of 2001, but, to date, it has not been included in the official vaccination schedule of the public health system. ⋯ After PCV7 introduction in our area, rates of S. pneumoniae OB caused by vaccine serotypes decreased significantly despite only moderate use of the vaccine in our population.
-
Pediatr. Infect. Dis. J. · Jul 2007
Case ReportsLumboperitonial shunt infection due to Chryseobacterium indologenes.
Chryseobacterium indologenes central nervous system infection has not been reported. We present a case of lumboperitoneal shunt infection caused by C. indologenes successfully treated with trimethoprim-sulfamethoxazole and rifampin in a pediatric patient. Forty-three additional cases of C. indologenes non-central nervous system infections reported in the English medical literature were reviewed. Risk factors for C. indologenes infections include underlying medical illnesses, underlying immunocompromising conditions and presence of indwelling intravascular devices.
-
Pediatr. Infect. Dis. J. · Jun 2007
Determination of extended-interval gentamicin dosing for neonatal patients in developing countries.
Infectious diseases account for an estimated 36% of neonatal deaths globally. The purpose of this study was to determine safe, effective, simplified dosing regimens of gentamicin for treatment of neonatal sepsis in developing countries. ⋯ Safe, therapeutic gentamicin dosing regimens were identified for treatment of neonatal sepsis in developing country settings. Administration of these doses could be simplified through use of Uniject, a prefilled, single injection device designed to make injections safe and easy to deliver in developing country settings.
-
Pediatr. Infect. Dis. J. · May 2007
Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants.
The pharmacokinetics of valganciclovir were studied in 8 infants ranging in age from 4 to 90 days (mean 20 days). We suggest that doses of 15 mg/kg given twice daily may be suitable for neonates and young infants.